Message Center
{{ messageCount }} Messages
Watched Genes
{{$index + 1}}. {{ watchedObject.symbol }} (RGD ID:{{watchedObject.rgdId}})
Watched Ontology Terms
{{$index + 1}}. {{ watchedTerm.term }} ({{watchedTerm.accId}})
{{gene.symbol}}: {{ gene.description }}
Save what matters to you
{{ loginError }}
Sign in with your RGD account
Gene: Selenoi (selenoprotein I) Rattus norvegicus
Analyze
Symbol:
Selenoi
Name:
selenoprotein I
RGD ID:
1560938
Description:
Predicted to have ethanolaminephosphotransferase activity. Predicted to be involved in phosphatidylethanolamine biosynthetic process. Predicted to localize to Golgi apparatus and endoplasmic reticulum membrane. Human ortholog(s) of this gene implicated in hereditary spastic paraplegia. Orthologous to human SELENOI (selenoprotein I); INTERACTS WITH 17alpha-ethynylestradiol; 2,3,7,8-tetrachlorodibenzodioxine; 4,4'-diaminodiphenylmethane.
Type:
protein-coding
RefSeq Status:
REVIEWED
Also known as:
Ept1; ethanolaminephosphotransferase 1; ethanolaminephosphotransferase 1 (CDP-ethanolamine-specific); LOC362713; MGC188326; RGD1560938; Seli; similar to mKIAA1724 protein
RGD Orthologs
Alliance Genes
More Info
more info ...
More Info
Latest Assembly:
Rnor_6.0 - RGSC Genome Assembly v6.0
Position:
Rat Assembly Chr Position (strand) Source Genome Browsers JBrowse NCBI UCSC Ensembl Rnor_6.0 6 27,473,748 - 27,512,287 (-) NCBI Rnor6.0 Rnor_6.0 rn6 Rnor6.0 Rnor_6.0 Ensembl 6 27,473,748 - 27,512,287 (-) Ensembl Rnor6.0 rn6 Rnor6.0 Rnor_5.0 6 37,285,872 - 37,323,978 (-) NCBI Rnor5.0 Rnor_5.0 rn5 Rnor5.0 RGSC_v3.4 6 26,058,654 - 26,096,822 (-) NCBI RGSC3.4 rn4 RGSC3.4 Celera 6 25,550,258 - 25,588,218 (-) NCBI Celera Cytogenetic Map 6 q14 NCBI
JBrowse:
View Region in Genome Browser (JBrowse)
Model
Imported Disease Annotations - ClinVar
Imported Disease Annotations - OMIM
1,2-dimethylhydrazine decreases expression ISO RGD:1618397 6480464 1, 2-Dimethylhydrazine results in decreased expression of EPT1 mRNA CTD PMID:22206623 17alpha-ethynylestradiol increases expression EXP 6480464 Ethinyl Estradiol results in increased expression of SELENOI mRNA CTD PMID:29097150 2,3,7,8-tetrachlorodibenzodioxine multiple interactions ISO RGD:1618397 6480464 [TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of SELENOI mRNA more ... CTD PMID:19654925 more ... 2,3,7,8-tetrachlorodibenzodioxine decreases expression ISO RGD:1618397 6480464 Tetrachlorodibenzodioxin results in decreased expression of EPT1 mRNA CTD PMID:28213091 , PMID:28238261 2,3,7,8-tetrachlorodibenzodioxine affects expression EXP 6480464 Tetrachlorodibenzodioxin affects the expression of SELENOI mRNA CTD PMID:22298810 2-methylcholine affects expression ISO RGD:1604559 6480464 beta-methylcholine affects the expression of SELENOI mRNA CTD PMID:21179406 4,4'-diaminodiphenylmethane decreases expression EXP 6480464 4, 4'-diaminodiphenylmethane results in decreased expression of SELENOI mRNA CTD PMID:30723492 acrylamide increases expression EXP 6480464 Acrylamide results in increased expression of SELENOI mRNA CTD PMID:28959563 aflatoxin B1 increases methylation ISO RGD:1604559 6480464 Aflatoxin B1 results in increased methylation of SELENOI gene CTD PMID:27153756 arsane affects methylation ISO RGD:1604559 6480464 Arsenic affects the methylation of SELENOI gene CTD PMID:25304211 arsenic acid decreases expression ISO RGD:1618397 6480464 arsenic acid results in decreased expression of SELENOI mRNA CTD PMID:19429247 arsenic atom affects methylation ISO RGD:1604559 6480464 Arsenic affects the methylation of SELENOI gene CTD PMID:25304211 arsenite(3-) decreases expression ISO RGD:1618397 6480464 arsenite results in decreased expression of SELENOI mRNA CTD PMID:19429247 benzo[a]pyrene multiple interactions ISO RGD:1618397 6480464 Benzoapyrene promotes the reaction [AHR protein binds to SELENOI promoter] CTD PMID:19654925 bisphenol A increases expression EXP 6480464 bisphenol A results in increased expression of SELENOI mRNA CTD PMID:29097150 bisphenol A decreases expression EXP 6480464 bisphenol A results in decreased expression of SELENOI mRNA CTD PMID:30816183 cadmium atom increases expression ISO RGD:1604559 6480464 Cadmium results in increased expression of SELENOI mRNA CTD PMID:23369406 carbon nanotube decreases expression ISO RGD:1618397 6480464 Nanotubes, Carbon analog results in decreased expression of SELENOI mRNA CTD PMID:25620056 copper(II) sulfate decreases expression ISO RGD:1604559 6480464 Copper Sulfate results in decreased expression of SELENOI mRNA CTD PMID:19549813 coumestrol increases expression ISO RGD:1604559 6480464 Coumestrol results in increased expression of SELENOI mRNA CTD PMID:19167446 dibenz[a,h]anthracene decreases expression ISO RGD:1618397 6480464 1 more ... CTD PMID:26377693 diethylstilbestrol affects response to substance EXP 6480464 SELENOI gene affects the susceptibility to Diethylstilbestrol CTD PMID:15687265 dioxygen multiple interactions ISO RGD:1618397 6480464 [NFE2L2 protein affects the susceptibility to Oxygen] which affects the expression of EPT1 mRNA CTD PMID:30529165 dorsomorphin multiple interactions ISO RGD:1604559 6480464 [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-5-benzo1 more ... CTD PMID:27188386 formaldehyde decreases expression ISO RGD:1604559 6480464 Formaldehyde results in decreased expression of SELENOI mRNA CTD PMID:23649840 formaldehyde increases expression ISO RGD:1604559 6480464 Formaldehyde results in increased expression of SELENOI mRNA CTD PMID:20655997 indole-3-methanol multiple interactions EXP 6480464 [indole-3-carbinol co-treated with Diethylnitrosamine co-treated with Acetylcysteine] results in decreased expression of SELENOI mRNA CTD PMID:22129741 methamphetamine decreases expression ISO RGD:1618397 6480464 Methamphetamine results in decreased expression of SELENOI mRNA CTD PMID:26307267 methylmercury chloride increases expression ISO RGD:1604559 6480464 methylmercuric chloride results in increased expression of EPT1 mRNA CTD PMID:28001369 N-acetyl-L-cysteine multiple interactions EXP 6480464 [indole-3-carbinol co-treated with Diethylnitrosamine co-treated with Acetylcysteine] results in decreased expression of SELENOI mRNA CTD PMID:22129741 N-nitrosodiethylamine multiple interactions EXP 6480464 [indole-3-carbinol co-treated with Diethylnitrosamine co-treated with Acetylcysteine] results in decreased expression of SELENOI mRNA CTD PMID:22129741 nickel atom increases expression ISO RGD:1604559 6480464 Nickel results in increased expression of SELENOI mRNA CTD PMID:25583101 oxaliplatin multiple interactions EXP 6480464 [oxaliplatin co-treated with Topotecan] results in decreased expression of SELENOI mRNA CTD PMID:25729387 panobinostat multiple interactions ISO RGD:1604559 6480464 [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-5-benzo1, 3dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-ylbenzamide] results in increased expression of SELENOI mRNA CTD PMID:27188386 panobinostat increases expression ISO RGD:1604559 6480464 panobinostat results in increased expression of SELENOI mRNA CTD PMID:26272509 paracetamol affects expression ISO RGD:1618397 6480464 Acetaminophen affects the expression of SELENOI mRNA CTD PMID:17562736 phenobarbital affects expression ISO RGD:1618397 6480464 Phenobarbital affects the expression of SELENOI mRNA CTD PMID:23091169 phenobarbital increases expression ISO RGD:1618397 6480464 Phenobarbital results in increased expression of SELENOI mRNA CTD PMID:19270015 phenylmercury acetate increases expression ISO RGD:1604559 6480464 Phenylmercuric Acetate results in increased expression of SELENOI mRNA CTD PMID:26272509 phenylmercury acetate multiple interactions ISO RGD:1604559 6480464 [NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-5-benzo1, 3dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-ylbenzamide] results in increased expression of SELENOI mRNA CTD PMID:27188386 pirinixic acid increases expression ISO RGD:1618397 6480464 pirinixic acid results in increased expression of SELENOI mRNA CTD PMID:18301758 pirinixic acid multiple interactions ISO RGD:1604559 6480464 [pirinixic acid binds to and results in increased activity of PPARA protein] which results in increased expression of SELENOI mRNA CTD PMID:19710929 propiconazole increases expression ISO RGD:1618397 6480464 propiconazole results in increased expression of SELENOI mRNA CTD PMID:21278054 rotenone decreases expression EXP 6480464 Rotenone results in decreased expression of SELENOI mRNA CTD PMID:28374803 SB 431542 multiple interactions ISO RGD:1604559 6480464 [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-5-benzo1 more ... CTD PMID:27188386 sunitinib increases expression ISO RGD:1604559 6480464 Sunitinib results in increased expression of SELENOI mRNA CTD PMID:31533062 topotecan multiple interactions EXP 6480464 [oxaliplatin co-treated with Topotecan] results in decreased expression of SELENOI mRNA CTD PMID:25729387 troglitazone decreases expression ISO RGD:1618397 6480464 troglitazone results in decreased expression of SELENOI mRNA CTD PMID:28973697 uranium atom affects expression ISO RGD:1604559 6480464 Uranium affects the expression of SELENOI mRNA CTD PMID:15672453 valproic acid affects expression ISO RGD:1604559 6480464 Valproic Acid affects the expression of SELENOI mRNA CTD PMID:23179753 valproic acid multiple interactions ISO RGD:1604559 6480464 [NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-5-benzo1, 3dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-ylbenzamide] results in increased expression of SELENOI mRNA CTD PMID:27188386 valproic acid increases expression ISO RGD:1604559 6480464 Valproic Acid results in increased expression of EPT1 mRNA, Valproic Acid results in increased expression of SELENOI mRNA CTD PMID:24935251 more ... valproic acid decreases methylation ISO RGD:1604559 6480464 Valproic Acid results in decreased methylation of EPT1 gene CTD PMID:29154799 vinclozolin affects expression EXP 6480464 vinclozolin affects the expression of SELENOI mRNA CTD PMID:23034163 zinc atom multiple interactions ISO RGD:1604559 6480464 [PCI 5002 co-treated with Zinc] results in increased expression of SELENOI mRNA CTD PMID:18593933 zinc(0) multiple interactions ISO RGD:1604559 6480464 [PCI 5002 co-treated with Zinc] results in increased expression of SELENOI mRNA CTD PMID:18593933
References
Additional References at PubMed
Genomics
QTLs in Region (Rnor_6.0)
738023 Alc17 Alcohol consumption QTL 17 3.1 0.003 consumption behavior trait (VT:0002069) ethanol drink intake rate to body weight ratio (CMO:0001616) 6 1 35623029 Rat 1354616 Despr12 Despair related QTL 12 0.0012 locomotor behavior trait (VT:0001392) amount of experiment time spent in a discrete space in an experimental apparatus (CMO:0000958) 6 1 35623029 Rat 1549905 Stresp10 Stress response QTL 10 6.83 0.0066 stress-related behavior trait (VT:0010451) number of approaches toward negative stimulus before onset of defensive burying response (CMO:0001960) 6 1 35623029 Rat 2300176 Bmd51 Bone mineral density QTL 51 11.7 0.0001 femur mineral mass (VT:0010011) bone mineral density (CMO:0001226) 6 1 35623029 Rat 2300190 Bmd52 Bone mineral density QTL 52 11.2 0.0001 femur mineral mass (VT:0010011) volumetric bone mineral density (CMO:0001553) 6 1 35623029 Rat 1331743 Uae28 Urinary albumin excretion QTL 28 4.5 urine albumin amount (VT:0002871) urine albumin level (CMO:0000130) 6 1 41917988 Rat 9589048 Scfw3 Subcutaneous fat weight QTL 3 4.57 0.001 subcutaneous adipose mass (VT:1000472) abdominal subcutaneous fat pad weight (CMO:0002069) 6 1 42388212 Rat 9589129 Insul24 Insulin level QTL 24 19.06 0.001 blood insulin amount (VT:0001560) plasma insulin level (CMO:0000342) 6 1 42388212 Rat 7411603 Foco13 Food consumption QTL 13 5.5 0.001 eating behavior trait (VT:0001431) feed conversion ratio (CMO:0001312) 6 1 42388212 Rat 7411542 Bw127 Body weight QTL 127 5.5 0.001 body mass (VT:0001259) body weight gain (CMO:0000420) 6 1 42388212 Rat 8552962 Pigfal16 Plasma insulin-like growth factor 1 level QTL 16 9.4 blood insulin-like growth factor amount (VT:0010479) plasma insulin-like growth factor 1 level (CMO:0001299) 6 1 42388212 Rat 2293709 Bss23 Bone structure and strength QTL 23 5.18 0.0001 femur morphology trait (VT:0000559) femur cross-sectional area (CMO:0001661) 6 1 43665660 Rat 2293650 Bss31 Bone structure and strength QTL 31 5.05 0.0001 femur strength trait (VT:0010010) femur midshaft polar moment of inertia (CMO:0001669) 6 1 43665660 Rat 2293656 Bss28 Bone structure and strength QTL 28 6.79 0.0001 femur morphology trait (VT:0000559) femur midshaft cortical cross-sectional area (CMO:0001663) 6 1 43665660 Rat 7411584 Foco4 Food consumption QTL 4 4.3 0.001 eating behavior trait (VT:0001431) feed conversion ratio (CMO:0001312) 6 1 44015370 Rat 738024 Sach5 Saccharine consumption QTL 5 3.9 0.00039 consumption behavior trait (VT:0002069) saccharin intake volume to total fluid intake volume ratio (CMO:0001601) 6 1 44570292 Rat 2301972 Bp325 Blood pressure QTL 325 4.8 arterial blood pressure trait (VT:2000000) systolic blood pressure (CMO:0000004) 6 1 75623393 Rat 1359023 Bp272 Blood pressure QTL 272 2.5 arterial blood pressure trait (VT:2000000) mean arterial blood pressure (CMO:0000009) 6 1120393 28706721 Rat 2292589 Emca10 Estrogen-induced mammary cancer QTL 10 0.048 mammary gland integrity trait (VT:0010552) post-insult time to mammary tumor formation (CMO:0000345) 6 1120393 46120393 Rat 1354664 Slep2 Serum leptin concentration QTL 2 4.49 blood leptin amount (VT:0005667) serum leptin level (CMO:0000780) 6 1120393 75023446 Rat 1576309 Emca7 Estrogen-induced mammary cancer QTL 7 4 mammary gland integrity trait (VT:0010552) mammary tumor number (CMO:0000343) 6 2537030 111715717 Rat 1578665 Bss16 Bone structure and strength QTL 16 4.4 femur morphology trait (VT:0000559) bone trabecular cross-sectional area (CMO:0002311) 6 6161722 76002731 Rat 1578668 Bmd14 Bone mineral density QTL 14 3.8 femur mineral mass (VT:0010011) total volumetric bone mineral density (CMO:0001728) 6 6161722 76002731 Rat 4145119 Mcs25 Mammary carcinoma susceptibility QTL 25 0.0001 mammary gland integrity trait (VT:0010552) ratio of deaths to total study population during a period of time (CMO:0001023) 6 7009971 115379601 Rat 634322 Bw12 Body weight QTL 12 0 body mass (VT:0001259) body weight (CMO:0000012) 7 10173862 55173862 Rat 1300128 Rf16 Renal function QTL 16 3.89 renal blood flow trait (VT:2000006) absolute change in renal blood flow rate (CMO:0001168) 6 13122958 34367603 Rat 1300164 Rf15 Renal function QTL 15 3.12 renal blood flow trait (VT:2000006) absolute change in renal blood flow rate (CMO:0001168) 6 13122958 57516539 Rat 10401812 Kidm54 Kidney mass QTL 54 kidney mass (VT:0002707) both kidneys wet weight (CMO:0000085) 6 16810107 61810107 Rat 10401800 Kidm49 Kidney mass QTL 49 kidney mass (VT:0002707) both kidneys wet weight (CMO:0000085) 6 16810107 61810107 Rat 8552910 Pigfal5 Plasma insulin-like growth factor 1 level QTL 5 4.3 blood insulin-like growth factor amount (VT:0010479) plasma insulin-like growth factor 1 level (CMO:0001299) 6 19417887 64417887 Rat 1641898 Colcr4 Colorectal carcinoma resistance QTL4 3.71 0.0007 intestine integrity trait (VT:0010554) well differentiated malignant colorectal tumor surface area measurement (CMO:0002077) 6 21515302 65784818 Rat 2293839 Kiddil2 Kidney dilation QTL 2 4.8 kidney pelvis morphology trait (VT:0004194) hydronephrosis severity score (CMO:0001208) 6 22042854 84763421 Rat 2293841 Kiddil4 Kidney dilation QTL 4 4.4 kidney pelvis morphology trait (VT:0004194) hydronephrosis severity score (CMO:0001208) 6 22042854 84763421 Rat
